Loading insider details...
Beta
Latest Form 4 (Jun 12, 2026): Grant/Award of 25,800 GLUE shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 25,800 | n/a |
| Jun 8, 2026 | Aclaris Therapeutics, Inc. (ACRS) | Exercise/Conversion | 11,580 | n/a |
| Jun 16, 2025 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 30,700 | n/a |
| Jun 9, 2025 | Aclaris Therapeutics, Inc. (ACRS) | Exercise/Conversion | 4,793 | n/a |
| Jun 13, 2024 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 22,100 | n/a |
| Jun 10, 2024 | Aclaris Therapeutics, Inc. (ACRS) | Grant/Award | 15,750 | n/a |
| Jun 4, 2024 | Aclaris Therapeutics, Inc. (ACRS) | Exercise/Conversion | 4,660 | n/a |
| Jun 15, 2023 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 20,500 | n/a |
| Jun 5, 2023 | Aclaris Therapeutics, Inc. (ACRS) | Exercise/Conversion | 4,507 | n/a |
| Nov 14, 2022 | Aclaris Therapeutics, Inc. (ACRS) | Sale | 11,395 | $194.0K |